Search
Bithionol
go.drugbank.com/drugs/DB04813ApprovedWithdrawnApprovals of the NDA's for bithionol drug products were withdrawn on October 24, 1967 (see the Federal Register of October 31, 1967 (32 FR 15046)). … Bithionol, formerly marketed as an active ingredient in various topical drug products, was shown to be a potent photosensitizer with the potential to cause serious skin disorders.
Categories: Anti-Acne Preparations for Topical UseAmisulpride
go.drugbank.com/drugs/DB06288ApprovedInvestigationalIn the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea and vomiting in adults, either as monotherapy or in combination with another antiemetic agent of … [A6752, L32764] Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders
Synonyms: 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamideDipyrithione
go.drugbank.com/drugs/DB11327Approved[A32829] Interestingly, dipyrithione has been studied and shown to have cytotoxic and potent broad-spectrum antitumor activity, which suggests a potential basis for an anticancer drug development. … Dipyrithione, a bactericidal and fungicidal pyrithione derivate, was formulated as Crimanex anti-dandruff shampoo, but is no longer available.
Tenapanor
go.drugbank.com/drugs/DB11761ApprovedInvestigationalIn October 2023, tenapanor was approved for the treatment of chronic kidney disease.[L48511] … Tenapanor is a novel, small molecule medication approved in September 2019 for the treatment of constipation-predominant irritable bowel-syndrome (IBS-C).
Categories: Drugs for ConstipationCapivasertib
go.drugbank.com/drugs/DB12218ApprovedInvestigationalTherefore, targeting the PIK3/AKT pathway presents a promising approach for the treatment of breast cancer, leading to the development of capivasertib, a pan-AKT kinase inhibitor. … [A262021,A262026,A262031] On November 17th, 2023, capivasertib, under the brand name TRUQAP, was approved by the FDA for the treatment of adult patients HR-positive, HER2-negative locally advanced or
Centanafadine
go.drugbank.com/drugs/DB14841ApprovedInvestigational[L63806] Its mechanism in ADHD is unclear, but its efficacy may be mediated by this triple reuptake inhibition, which increases the availability of all three neurotransmitters in pathways involved in attention … age or weight.
Categories: Psychostimulants, Agents Used for ADHD and Nootropics, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeGadopiclenol
go.drugbank.com/drugs/DB17084ApprovedInvestigationalIt is indicated for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system and the body. … [A254002] Gadopiclenol has high kinetic stability and a high r1 relaxivity, allowing it to be used at lower doses than classic extracellular GBCAs.
Terazosin
go.drugbank.com/drugs/DB01162ApprovedInvestigationalTerazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label][A176831].
Categories: Antihypertensive Agents Indicated for HypertensionSunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalFor these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. … On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).
Bendroflumethiazide
go.drugbank.com/drugs/DB00436ApprovedInvestigationalA thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders.
Categories: Antihypertensive Agents Indicated for Hypertension